Objective: hepatitis c virus (hcV) infection is a major cause of liver disease. since symptoms of chronic liver disease usually appear only late in the course of the disease, infected individuals may remain undiagnosed until advanced disease has developed. We aimed to investigate which screening strategies would be most effective to detect individuals unaware of their infection.
Introduction
hepatitis c virus (hcV) infection is a major cause of liver disease and liver-related mortality [1] [2] [3] . hcV prevalence of up to 15% has been reported in some countries; it may also be up to 1% in several high-income countries [1, 4] . about 40,000 people (0.5% of the general population) were estimated to be chronically infected with hcV in switzerland in 2016 [5] .
as in many high-income countries, the majority of reported cases in switzerland is concentrated among injection drug users (iDU) [5] [6] [7] [8] . after 2000, the number of new infections among iDU has decreased following the intensified implementation of harmreduction measures [5, 7] . sexual transmission of hcV is possible but rare in the general population [9, 10] . however, increased hcV incidence has been reported among hiV-positive men who have sex with men (MsM) [5, 11] . Most health care-associated hcV transmissions occurred before blood products were systematically screened for hcV and before adequate methods were introduced to prevent transmission by invasive medical procedures [5, 12] . increased hcV prevalence is also found in other groups such as migrants originating from high-prevalence countries [5, 12, 13] . in 2014, direct-acting antivirals (Daa) with a cure rate of >90% became available and are now the gold standard of hcV treatment [12, 14] . since October 2017, Daa treatment has been reimbursed for all hcV-infected patients in switzerland, regardless of liver disease stage [6, 15] . infected persons may be unaware of their infection for decades [16] : liver-related complications develop slowly and may not appear for at least 10 years after infection [16, 17] . consequently, case detection based on symptoms and self-reported risk factors may be insufficient. some countries have implemented policies of wider screening: for example, in France it is now recommended that every adult is tested at least once during their lifetime [18] . in switzerland, like in many other countries, blood, organ and cell donations are systematically screened for hcV, and hcV testing is recommended for persons with clinical symptoms of hepatitis or medical, demographic, occupational or other risk factors associated with hcV [12] . however, there is no national policy or action plan to screen wider population groups [6, 12] . Broader screening may accelerate the identification of hcV-infected individuals and, together with Daa treatment, reduce the longterm burden of the disease. We therefore developed a mathematical model to explore the impact of different screening strategies on hcV diagnosis and the number of cases of decompensated cirrhosis (Dc), hepatocellular carcinoma (hcc) and liver-related deaths in switzerland.
Methods

Model structure
We developed a mathematical model using the r package gems [19] to quantify hcV disease progression. in gems, disease progression is represented by a directed acyclic graph of health states. in each state, transition times to all possible destination states are sampled. The minimum of these times determines when and to which state the patient will move. The process is repeated until the patient reaches a terminal state. We adapted the model structure of Zahnd et al. [20] and simulated cohorts of patients from the time of infection until death. The patients progress along two dimensions, representing the progression of liver disease and the course of hcV infection including the cascade of care ( Figure 1 ). The stage of liver disease is defined according to the MeTaVir scoring system (F0-F4) followed by Dc, hcc and liver transplantation (lT). The progression of hcV infection and care is divided into acute infection, chronic undiagnosed infection, chronic diagnosed infection, first treatment, second treatment and undetectable hcV. Death was represented using four separate states depending on the cause: liver-related, hiV-related, iDUrelated and other causes. The patients who spontaneously clear hcV or achieve sustained virological response (sVr) after treatment move to the states with undetectable hcV viral load. We assumed that spontaneous clearance or achievement of sVr decreased the fibrosis progression rates by 90% [20] . Fibrosis regression after sVr was not considered in the model. For simplicity, we did not include a separate state for failing treatment. We only considered treatment with Daa and excluded patients treated successfully with pre-Daa treatment [21] [22] [23] [24] . We assumed that patients could be treated with Daa in stage F2 or above between 2014 and 2017, and regardless of fibrosis stage from 2018 onwards [6] . Patients who were diagnosed before 2014 started treatment after a random delay between 0 and 15 years after becoming eligible for treatment. Patients diagnosed from 2014 onwards were treated on average 6 months after meeting the eligibility criteria [25] . Probability of achieving sVr was 98% regardless of genotype or other characteristics [14] . at the beginning of the simulation, patients were assigned the following characteristics: birth year, age at infection, sex, region of origin, hiV co-infection and its duration, alcohol consumption, high-risk sexual MsM behaviour, and the duration of injecting drug use (supplementary Tables 1-2 ).
Data sources
We obtained the distribution of baseline characteristics among the currently diagnosed patients from the swiss Federal Office of Public health (FOPh) notification database (supplementary Figure 1 ). This database contains all notified cases of hcV in switzerland since 1988. We used the data on age, sex, region of geographic origin and the expected route of transmission at the year of notification. We assumed that half of the patients in the database who were treated in the pre-Daa era achieved sVr and were thus excluded from our analyses [21, 23] . The FOPh database does not include information on alcohol consumption or hiV co-infection. These characteristics were estimated from the swiss hepatitis c cohort study (sccs) [26] by matching the patients in the FOPh database with the patients in the sccs based on the year of infection and common baseline characteristics. When there were no patients in the sccs for a particular combination of infection year and baseline characteristics, we assumed that the proportions of individuals with severe, moderate and abstinent alcohol consumption were equal and that individuals with high-risk MsM behaviour were hiV co-infected. Years of starting and ending active drug use, containing also substitution therapy, were assigned to all simulated iDU. similarly, we assigned each hiV co-infected patient a year of hiV infection.
We reviewed the literature to parameterise the model. We chose parameter values that would best represent the situation in switzerland, consulting experts if necessary. We parameterised fibrosis progression from F0 to F4 assuming stage-and age-dependent rates as proposed by razavi et al. [27] . and harris et al. [28] .
(supplementary Tables 3-5 ). Parameters for liver-related mortality and the cascade of hcV infection and care can be found in supplementary Tables 6-7.
Fitting the model to the data of the local hcV registry
We first simulated generic cohorts of patients for all combinations of baseline characteristics. Then, we assigned each simulated patient a weight corresponding to the representativeness in the true hcV-infected population in switzerland. The weights were based on the analyses of the FOPh and sccs databases for the population diagnosed by 2015, and on our assumptions concerning the population that had not yet been diagnosed. We first determined the weights for the simulated individuals corresponding to the diagnosed patients in the FOPh data and used the model to back-calculate the year of infection in this population (supplementary Figures 2-3 ). We assumed that the number of annual new infections among individuals of swiss origin would follow approximately the distribution of infection years among people already diagnosed, with the probability of being diagnosed by year 2015 slightly decreasing over time. We then modified the number of new infections each year to account for the expected peak in new infections around the early 1990s, during the time of the major changes in drug policy [7, 29, 30] . For the patients of foreign origin, we assumed a decline in new infections over the years, influenced by differences in migration patterns and the hcV prevalence in the respective countries of origin [5, 6, 13] . The size of the viremic population living in switzerland was assumed to be approximately 40,000 in 2016 [5] .
We applied the distribution of baseline characteristics of the diagnosed patients infected in a particular year to the undiagnosed individuals infected in the same year. We assumed the number of annual new infections in the future would remain at the level of 2015 (supplementary Table 8 ).
screening strategies
We modelled a baseline scenario and five screening interventions from the year 2018 onwards. all five interventions were built on top of the baseline scenario. in the baseline scenario, hcV testing continued in the future as in 2017 (Table 1) . With a scenario of intensified iDU screening, the rate of testing active iDU was increased from 0.5 to 1.0 per person-year. in the origin-based scenario, people from southern europe, africa and asia were tested with a rate of 0.5 per person-year. in the birth-cohort screening scenario, the rate 0.5 per person-year was applied to individuals born between 1951 and 1985 [31] , and with universal screening, to all individuals. in all scenarios, the patients had an hcV antibody test, followed by a confirmatory nucleic acid test in case of a positive antibody test result.
sensitivity analyses
We conducted six sensitivity analyses (s1-s6) to address the uncertainty around parameters and assumptions (supplementary Table 9 ). First, we conducted a sensitivity analysis around the size of the viremic population in 2016, assuming it was either 40% higher (sensitivity analysis s1) or 10% lower (s2) than in the main analysis. second, we assumed that the proportion of individuals with high-risk behaviour was either higher (s3) or lower (s4) among the undiagnosed than the diagnosed population infected in the same year. Third, we reduced the rate of hcV diagnoses among iDU before 2018 (s5). Finally, we investigated the effect of fibrosis progression rates by using an alternative parameterisation of the liver disease progression (s6), assuming a constant rate of fibrosis progression across all stages [2] .
Results
screening scenarios in the baseline scenario, on average 650 hcV-infected individuals were diagnosed annually during the first 4 years (2018-2021), and this number decreased to about 300 individuals by 2030 ( Figure 2 ). intensified screening among active iDU (660 diagnoses annually during years 2018-2021, 1% increase from baseline) and screening former iDU (760 diagnoses annually during years 2018-2021, 17% increase) led to similar results. screening based on geographic origin slightly increased the number of diagnoses during the first 4 years, with 830 (28% increase from baseline) annual diagnoses. in the following years, the number remained stable in all of these four scenarios, at about 500 per year. With birth-cohort and universal screening, the number of new diagnoses was substantially higher in the year 2018 than in the other scenarios. Birth-cohort and universal screening strategies could identify on average 1420 (118% increase from baseline) and 1940 (198% increase from baseline) patients per year in 2018-2021, respectively. From 2022, the number started to decrease, reaching 140 (birth-cohort) and 100 (universal) diagnoses in 2029.
On average, 4720 patients can be expected to achieve sVr annually within the years 2018-2021 in the baseline scenario. The corresponding numbers (with increase compared with baseline) were 4760 (1%) for the intensified screening of active iDU, 5020 (6%) for the screening of former iDU, 4960 (5%) for the originbased screening, 6000 (27%) for birth-cohort screening and 6600 (40%) for universal screening. From 2022 onwards the average number of patients achieving sVr ranged from 1200 to 2400 per year across the strategies. 50,000 40,000 30,000 20,000 10,000
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The model showed no major differences in liver-related morbidity and mortality between the scenarios during the years 2018-2029 (supplementary Table 10 ). The total number of cases of Dc, hcc and liver-related deaths within the period 2018-2029 ranged from 960 to 1430, 200 to 350 and 1700 to 2000, respectively, across the screening strategies ( Figure 4 ). The differences among the strategies are likely due to stochastic variability.
sensitivity analyses
The annual number of new infections stayed around 1000 until the early 1980s in the main analysis, and started to increase thereafter, peaking at 1900 during the years 1995-1999 and followed by a decrease ( Figure 5 ). a major difference was seen in the sensitivity analysis s1 with a larger viremic population: between 1971 and 1990, the number of new infections was twice as high as in the main analysis. There were no major differences between the main analysis and the analyses s2 and s5 in terms of newly infected individuals. however, for the analysis in which the diagnosis rate among iDU was lower (s5), the peak of new infections occurred 5-10 years earlier. The numbers of new infections in the analyses s3 and s4 were, by definition, the same as in the main analysis. in the analysis with constant fibrosis progression (s6) (supplementary Table 11 ), the number of liver-related deaths and cases of Dc and hcc were about half of those in the main analysis (supplementary Table 10 ).
regarding future projections, universal and birth-cohort screening yielded the same results in the main and sensitivity analyses (supplementary Figure 4 ). The only major difference was in the analysis with more high-risk individuals (s3), where the effect of screening former iDU in 2018 was similar to birth-cohort screening.
Discussion
Principal findings
We forecasted the impact of several hcV testing strategies on the number of new hcV diagnoses, the size of the viremic population and the magnitude of liver-related complications and deaths in switzerland between 2018 and 2029 using a disease progression model. Birth-cohort and universal screening seemed to be the most effective strategies for identifying the undiagnosed hcVinfected individuals within the next 4 years and for reducing the size of the viremic population. however, we could not show a clear difference in liver complications or mortality between the screening strategies, most probably due to stochastic variability in the model. implementing broad strategies such as birth-cohort or universal screening requires testing a large low-prevalence population, indicating a high cost per diagnosis. The feasibility of such screening strategies should be studied from the acceptability and cost-effectiveness perspective. Universal screening of 8 million residents over the next 12 years to identify about 10,000 infections would add a considerable burden to switzerland's healthcare budget. The indirect costs related to false-positive and borderline test results should also be added [32] [33] [34] [35] . Therefore, although universal screening could reduce the hcV viremic population by 2030, implementing such strategy would be challenging. screening only the 3.6 million individuals born between 1951 and 1985 could halve the number of people tested [36] . studies from the Us have suggested that one-time birth-cohort screening could be cost-effective [37] [38] [39] [40] . however, the eldest individuals, who have the highest rate of disease progression and may otherwise be more difficult to detect on time, would not benefit from birth-cohort screening [2, 13] .
screening former iDU may also help to detect a substantial number of cases. however, the effectiveness of this strategy depends on the assumptions of the model. if we assumed that iDU were frequently tested in the past, screening former iDU provided almost no benefit. in contrast, assuming a considerably lower testing rate for active iDU in the past, screening of former iDU was almost as effective as birth-cohort screening, mainly because former iDU remained untested in the years of active drug use. identifying former iDU can, however, be challenging. Despite the pragmatic, harm reduction oriented drug policy of switzerland, persons who only occasionally injected drugs in the past will unlikely identify themselves as having been at risk for hcV infection [41] .
intensifying the screening of current iDU was, as expected, not very effective: we assumed a relatively high testing rate among iDU in our baseline scenario [5] [6] [7] 12] , although shortcomings of testing in this population are observed [7, 42, 43] .
liver-related mortality and the incidence of liver complications did not essentially differ between the scenarios. The observed differences were not systematic and thus mainly due to random variability. Furthermore, we only modelled the next 12 years. Therefore, we cannot exclude the possibility that screening would reduce mortality in the longer term. Background mortality also is a competing risk factor: patients who most benefit from additional screening tend to be older, and mortality is increased in persons with iDU [44] .
Our results show that the number of viremic individuals will likely decrease over time in all screening strategies: in 2030, we expect to have no more than 5000 viremic individuals in switzerland, with large-scale screening strategies even considerably less. This represents a multiple-fold decrease from the current level. Viremic individuals may transmit the virus onwards: however, the risk of transmission also depends on the risk behaviour. The analysed screening strategies target mainly populations outside the groups with most ongoing transmission such as active iDU and hiV-infected MsM. it is therefore unlikely that screening would substantially affect the transmission dynamics. nevertheless, the impact of screening on the number of new infections needs verification with a transmission model before conclusions can be made.
strengths and limitations
Our study is among the first to compare the effect of different hcV testing strategies on the epidemiological determinants of hcV infection in a nationwide setting. as in many other highincome countries, the epidemic in switzerland is concentrated among injecting drug users and hiV-infected MsM, but other population groups may have also been exposed through, for example, unsafe medical procedures or one-time use of intravenous drugs. The results should be therefore applicable in a wide range of settings. several mathematical models have estimated the progression, transmission and epidemiological and financial burden of hcV infection [45] [46] [47] [48] . These models were usually limited to a specific subpopulation or tailored to a particular research question, or they did not take into account the individual-level risk factors. Our study benefited also from a systematic collection of hcV notification data since 1988.
Our study has several limitations. First, transmission is not included in our model. The absolute numbers should be interpreted with caution, as these are sensitive to several external factors, such as ongoing transmission and migration. Moreover, the number of new infections is a fixed input and the model thus does not take into account the impact of future interventions that target transmission. second, to avoid complexity, we did not take into account the false-negative test results and retesting [49] . Falsenegative antibody tests can occur in very early infection and in immunosuppressed patients. however, as the majority of the hcVinfected population is not immunosuppressed [26] , false-negative antibody tests are likely rare and should not essentially impact the results. Third, there are some limitations and uncertainty around the model parameters, including fibrosis progression rates and the assumptions regarding the currently undiagnosed population. The true hcV prevalence and the baseline characteristics of the undiagnosed individuals are difficult to estimate and cannot be determined without the collection of new primary data. Fourth, we did not model treatment with interferon and ribavirin, and the data for Daa treatment are limited to the period from 2014 when Daa became widely available. as the aim of the study was to compare screening strategies for identifying the undiagnosed infected individuals, the restriction to Daa treatment should not essentially influence the results. exclusion of the pre-Daa therapy, however, complicates the validation of the model against past observations. Finally, the number of reported hcV-infected patients may be subject to various types of bias, such as possible inaccurate estimates of the number of hcV-infected persons who have emigrated or died.
Conclusion
among the testing scenarios that we studied, only large-scale screening strategies could accelerate hcV detection. screening people with a history of injecting drug use could also be effective, but the benefit of this strategy depends largely on assumptions of the characteristics of the undiagnosed population that cannot currently be verified. We could not show an essential difference in mortality and the incidence of Dc or hcc across the screening scenarios. Our results underline the need to explore the feasibility of different hcV testing strategies in low-prevalence settings, and to evaluate the potential financial burden of implementing a large-scale screening strategy.
Modeling the impact of different screening strategies for HCV infection in Switzerland: supplementary documents FOPh data
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FOPh: Federal Office of Public health; iDU: injecting drug user; MsM: men who have sex with men; sccs: swiss hepatitis c cohort study. a We used the fibrosis progression rates between MeTaVir stages F0 and F4 from a study conducted by razavi et al. [3] where fibrosis progression rates were back-calculated from data from the Us (Us surveillance, epidemiology and end results). They used the results of harris et al. [2] , who used a similar back-calculation method for calculating the fibrosis progression rates for patients from the UK, as a guidance. Dc → Death 0.129 [6, 7, 12, 13] hcc → Death 0.430 [6, 7, 12, 13] lT → Death (first year) 0.160 [6, 7, 12, 13] lT → Death (second year) 0.057 [6, 7, 12] Background mortality rates were taken from the Federal Office of statistics database. F4: cirrhosis; Dc: decompensated cirrhosis; hcc: hepatocellular carcinoma; lT: liver transplantation. Supplementary Table 11 . Disease progression rates between fibrosis stages F0 and F4 according to age at infection: parameters for analysis with constant fibrosis progression (sensitivity analysis s6) [8] Age at infection(years) Value Description 
Supplementary
